FDA Releases Q&A on ANDAs and Stability Testing - - BioPharm International

ADVERTISEMENT

FDA Releases Q&A on ANDAs and Stability Testing


FDA has released answers to questions received during the public comment period for the draft guidance document Stability Testing of Drug Substances and Products, Questions and Answers, published in the Federal Register on September 25, 2012 as well as responses to comments received on the draft of this guidance published in the Federal Register on August 27, 2013. The Q&A document responds to concerns regarding drug master files (DMFs), drug product manufacturing and packaging, and stability studies.

In the Q&A document, FDA clarifies the stability testing data recommendations for abbreviated new drug applications (ANDAs). According to the Q&A document, “the stability guidance covers all new ANDAs under the Federal Food, Drug, and Cosmetic Act, section 505 (j), and DMFs (Type II for drug substances that support the ANDAs). It does not apply to postapproval changes.”

FDA addresses questions related to the timing and amount of accelerated stability and long-term stability data required for an ANDA, intermediate stability study requirements, stability bracketing and matrixing, shelf-life calculation requirements, sample storage times, and more.

Source: FDA.gov

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here